Acinetobacter Pneumonia Therapeutics Market To Reach $470.96 Million By 2030

Acinetobacter Pneumonia Therapeutics Market Growth & Trends

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as β-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

 Request a free sample copy or view report summary: Acinetobacter Pneumonia Therapeutics Market Report

Acinetobacter Pneumonia Therapeutics Market Report Highlights

• The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease

• In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period

• Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections

• Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia

• In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials

• The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Acinetobacter Pneumonia Therapeutics Market Segmentation

Grand View Research has segmented the global acinetobacter pneumonia therapeutics market based on drug class, route of administration, and region:

Acinetobacter Pneumonia Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Cephalosporins

• Fluoroquinolone

• Glycylcycline

• Carbapenem

• β-Lactam antibiotics

• Sulbactam

• Aminoglycoside

• Polymyxins

• Tetracycline

• Sulfonamide

• Others

Acinetobacter Pneumonia Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral

• Oral

• Others

Acinetobacter Pneumonia Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • Spain

  • France

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Payers in the Acinetobacter Pneumonia Therapeutics Market

• Pfizer Inc.

• Merck & Co., Inc.

• GlaxoSmithKline plc (GSK)

• AstraZeneca Plc

• Novartis AG

• Johnson & Johnson

• Sanofi S.A.

• Bayer AG

• Basilea Pharmaceutica